Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on LifeMD, with a price target of $13.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yi Chen has given his Buy rating due to a combination of factors including LifeMD’s strong growth potential and strategic diversification. Despite a slight miss in the second quarter financial results and a lowered revenue guidance for 2025, the company’s telehealth revenue showed a significant year-over-year increase, and the active subscriber base also grew. This indicates a robust underlying demand for LifeMD’s services.
Additionally, the company’s expansion into high-demand clinical areas, such as behavioral health and women’s health, along with the scaling of its LifeMD+ membership program, positions it well for future growth. The recent paydown of long-term debt and a solid cash position further strengthen LifeMD’s financial stability. Yi Chen believes that the current share price pullback presents an attractive entry point for investors, supporting the Buy rating with an adjusted price target of $13.
Chen covers the Healthcare sector, focusing on stocks such as Anixa Biosciences, Clearside Biomedical, and Lipocine. According to TipRanks, Chen has an average return of -8.2% and a 36.38% success rate on recommended stocks.
In another report released yesterday, KeyBanc also maintained a Buy rating on the stock with a $12.00 price target.